Harbour Biomed gives Hong Kong new IPO dose
China's Harbour Biomed, a clinical-stage biopharmaceutical company, has hit the road for its up to HK$1.8bn ($230.4m) listing.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: